Xconomy’s Digital Events →
December 5th, 2007
GlaxoSmithKline has written Lexington, MA-based Synta Pharmaceuticals (NASDAQ: SNTA) a check for $80 million. The payment is the first installment under a cancer-drug development agreement that could ultimately be worth $1.1 billion for the Lexington firm.
Rebecca is Xconomy's co-founder. Follow @
From Our Editors · Special Report
Becoming the Cell & Gene Therapy Hub
From Our Editors · Podcast
The AI, Big Data, and R&D Boom
Sponsored · Webinar
Phenotypic Screening & Profiling to Understand a Compound's Disease Impact
© 2007-2021, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.